Immunogenicity of Trypanosoma cruzi Multi-Epitope Recombinant Protein as an Antigen Candidate for Chagas Disease Vaccine in Humans
Pathogens · 2025
DOI: 10.3390/pathogens14040342 ↗At a glance
Journal article in Pathogens, 2025. Written by Christian F Teh-Poot and 7 co-authors. Institution: Laboratorio de Parasitología, Centro de Investigaciones Regionales "Dr. Hideyo Noguchi", Universidad Autónoma de Yucatán, Mérida 97000, Mexico. Major MEDLINE topics: Trypanosoma cruzi, Chagas Disease, Epitopes, T-Lymphocyte, Antigens, Protozoan. Cited 3 times so far (Crossref); 82 references. The full text is freely available (open access, CC BY 4.0).
Abstract (original language)
Chagas disease, caused by the protozoan Trypanosoma cruzi (T. cruzi), is the most significant neglected tropical disease affecting individuals in the Americas. Currently, available drugs, such as nifurtimox and benznidazole (BZN), are both toxic and ineffective in the chronic phase of the disease. A promising alternative is the development of a Chagas disease vaccine, although this effort is hampered by the complexity of the parasite and HLA polymorphisms. In addition, the activation of epitope-specific CD8+ T cells is critical to conferring a robust cell-mediated immune response and protection by producing IFN-γ and perforin. Thus, the antigen (s) for the development of a Chagas vaccine or immunotherapy must include CD8+ T cell epitopes. In this study, we aimed to develop a multi-epitope recombinant protein as a novel human vaccine for Chagas disease. Sixteen database programs were used to predict de novo 40 potential epitopes for the HLA-A*02:01 allele. Nine out of the 40 predicted epitopes were able to elicit IFN-γ production in Peripheral Blood Mononuclear Cells (PBMCs) from Chagas patients. Molecular docking revealed a good binding affinity among the epitopes with diverse HLA molecules. Therefore, a recombinant multi-epitope protein including these nine T. cruzi CD8+ epitopes was expressed and demonstrated to recall an antigen-specific immune response in ex-vivo assays using PBMCs from Chagas patients with the HLA-A*02 allele. These findings support the development of this multi-epitope protein as a promising candidate human vaccine against Chagas disease.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Laboratorio de Parasitología, Centro de Investigaciones Regionales "Dr. Hideyo Noguchi", Universidad Autónoma de Yucatán, Mérida 97000, Mexico.
- Department of Chemistry and Biochemistry, Hampton University, Hampton, VA 23668, USA.
- Department of Tropical Medicine and Infectious Disease, Celia Scott Weatherhead School of Public Health and Tropical Medicine, Tulane University, New Orleans, LA 70112, USA.
ORCID profiles: Christian F Teh-Poot, Andrea Alfaro-Chacón, Eric Dumonteil, Julio Vladimir Cruz-Chan
Cite
APA
Teh-Poot, C. F., Alfaro-Chacón, A., Pech-Pisté, L. M., Rosado-Vallado, M. E., Asojo, O. A., Villanueva-Lizama, L. E., Dumonteil, E., & Cruz-Chan, J. V. (2025). Immunogenicity of Trypanosoma cruzi Multi-Epitope Recombinant Protein as an Antigen Candidate for Chagas Disease Vaccine in Humans. Pathogens. https://doi.org/10.3390/pathogens14040342
Vancouver
Teh-Poot CF, Alfaro-Chacón A, Pech-Pisté LM, Rosado-Vallado ME, Asojo OA, Villanueva-Lizama LE, et al. Immunogenicity of Trypanosoma cruzi Multi-Epitope Recombinant Protein as an Antigen Candidate for Chagas Disease Vaccine in Humans. Pathogens. 2025. doi:10.3390/pathogens14040342
BibTeX
@article{TehPoot2025,
author = {Teh-Poot, Christian F and Alfaro-Chacón, Andrea and Pech-Pisté, Landy M and Rosado-Vallado, Miguel E and Asojo, Oluwatoyin Ajibola and Villanueva-Lizama, Liliana E and Dumonteil, Eric and Cruz-Chan, Julio Vladimir},
title = {Immunogenicity of Trypanosoma cruzi Multi-Epitope Recombinant Protein as an Antigen Candidate for Chagas Disease Vaccine in Humans},
journal = {Pathogens},
year = {2025},
doi = {10.3390/pathogens14040342}
}
EUVIMED